Here are five things to know:
1. Researchers used an infusion center database to identify cases in which patients received infliximab for treatment of irritable bowel disease.
2. Approximately, 412 cases were included in the study.
3. Of the 412 cases, 52.7 percent required at least one dose optimization.
4. Dose optimization was more common in ulcerative colitis (67.2 percent) than in Crohn’s disease (46.3 percent).
5. The median time to dose optimization was 7 months ulcerative colitis cases and 27 months Crohn’s disease cases.
More articles on GI/endoscopy:
3 GI physicians in the news – July 10, 2015
New partnership creates virtual support community for IBD patients
Oregon House passes legislation requiring follow-up colonoscopy coverage: 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.